Compare INBX & NXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.